About the Authors

Anton Y. Peleg

apeleg@bidmc.harvard.edu

Affiliations Department of Microbiology, School of Biomedical Sciences, Monash University, Melbourne, Australia, Department of Infectious Diseases, The Alfred Hospital, Melbourne, Australia, Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

Spiros Miyakis

Affiliations Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America, 3rd Department of Medicine, Aristotle University, Thessaloniki, Greece

Doyle V. Ward

Affiliation Broad Institute, Boston, Massachusetts, United States of America

Ashlee M. Earl

Affiliation Broad Institute, Boston, Massachusetts, United States of America

Aileen Rubio

Affiliation Cubist Pharmaceuticals, Boston, Massachusetts, United States of America

David R. Cameron

Affiliation Department of Microbiology, School of Biomedical Sciences, Monash University, Melbourne, Australia

Satish Pillai

Affiliations Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

Robert C. Moellering Jr.

Affiliations Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

George M. Eliopoulos

Affiliations Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

Competing Interests

The authors have read the journal's policy and have the following conflicts; A.Y.P. has been to one advisory board meeting for Abbott Molecular and Ortho-McNeil-Janssen, and has received a speaker's honorarium from AstraZeneca and Merck Sharp & Dohme for one presentation each. G.M.E. has served on Scientific Advisory Boards for Cubist, Bayer Schering, Johnson & Johnson Pharmaceutical Research and Development, Novartis, Pfizer, Shionogi, Theravance; he has had research training support from Cubist, research contracts from Novexel, Pfizer and Theravance, and speaking honoraria from Novartis. He serves on the Board of Directors of the National Foundation for Infectious Diseases. R.C.M. has served as a consultant to Cubist, Forest, Merck, Novartis, Ortho Johnston and Johnston, Pfizer, Theravance, and Wyeth. A.R. is a scientist working for Cubist Pharmaceuticals and performed the lipid membrane studies. All other authors have no conflicts of interest. These potential conflicts of interest do not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: AYP DVW AME AR RCM GME. Performed the experiments: AYP SM DVW AME AR DRC SP. Analyzed the data: AYP SM DVW AME AR DRC SP RCM GME. Contributed reagents/materials/analysis tools: AYP SM DVW AME AR RCM GME. Wrote the paper: AYP. Revised the article critically for important intellectual content: AYP SM DVW AME AR DRC SP RCM GME. Final approval of the version to be published: AYP SM DVW AME AR DRC SP RCM GME.